Zipalertinib

泽帕厄替尼

Report date: 2026/03/11 20:02:12
NME

Base Information

Drug NameZipalertinib
Drug Alias NameCLN-081TAS-6417TPC-064
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR exon 20 insertion mutations inhibitors
TargetsEGFR exon 20 insertion mutations
Therapy Area/IndicationsPharmaceutical aidsCarcinoma, Non-Small-Cell LungLung Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[29] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesTaiho Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCullinan Therapeutics IncZai Lab (Shanghai) Co LtdTaiho Pharmaceutical Co Ltd +[4] 
Inactive CompaniesCullinan Pearl CorpBeijing Kendlewits Medical Consulting Co Ltd
Active IndicationsPharmaceutical aidsCarcinoma, Non-Small-Cell LungLung Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A